Fig. 1: Cohort overview. | Nature Communications

Fig. 1: Cohort overview.

From: Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial

Fig. 1

Cap capecitabine, FISH fluorescent in situ hybridization, GEA gastroesophageal adenocarcinoma, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, QW every week, Q2W every 2 weeks, Q3W every 3 weeks, Pac paclitaxel, PD progressive disease. aHER2-positive defined as IHC 3+ or IHC 2+/FISH+. bResponse evaluable analysis set.

Back to article page